Roflumilast

罗氟司特

Report date: 2025/10/24 20:00:54
NMEFirst In Class

Base Information

Drug NameRoflumilast
Drug Alias Nameroflumilastum罗米司特罗弗司特罗氟斯特Daxas +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphodieterase 4 inhibitors
TargetsPhosphodieterase 4
Therapy Area/IndicationsPlaque psoriasisSchizophreniaCognitive Dysfunction +[28] 
Global Approved IndicationsPulmonary Disease, Chronic Obstructive
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2010/07/05
Country/TerritoryCzechiaBelgiumCanada +[47] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPending
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSol-Gel Technologies LtdArcutis Biotherapeutics IncMaastricht University +[15] 
Inactive CompaniesMaastricht University Medical CenterThe University Of California DavisRevue Juridique Des Etudiants Et Etudiantes De L'Universite Laval Inc +[12] 
Active IndicationsPlaque psoriasisDepressive Disorder, MajorMemory +[21] 
Inactive IndicationsSchizophreniaCognitive DysfunctionMetabolic Syndrome +[7] 

Other Information

ATC CodeR03DX07
Related LinksWikipediaDrugBankKEGG